7-Day Limit on Initial Short-Acting Opioid Prescriptions
Customize your policy alerts
Sign up for all sanfranciscohealthplan policy alerts
Know when sanfranciscohealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
SFHP limits the first prescription for short-acting opioid medications for acute pain to a seven-day supply for members with no paid opioid claims in the prior 180 days; exemptions and prior authorization processes are specified and affect prescribers and certain patient groups.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial short-acting opioid prescriptions
Coverage and exception logic for initial short-acting opioid prescriptions
Cancer patients who have picked up an antineoplastic agent in past 180 days are automatically exempt; hospice and palliative care and chronic pain are automated exceptions per policy.
Providers who routinely write >7-day short-acting opioid prescriptions (e.g., oncology, palliative care) bypass the limit.
PA must include clinical rationale and expected duration; new members on chronic opioids require PA including diagnosis and expected duration.
This policy edit applies only to short-acting opioids and does not apply to long-acting opioid formulations; long-acting opioids are excluded from the seven-day initial supply restriction. Additionally, medications used for opioid use disorder (for example, buprenorphine prescribed for OUD) are not subject to this edit. Cancer patients are exempt from the initial-supply limit when there is evidence of recent antineoplastic therapy—specifically, if the member has picked up an antineoplastic agent in the past 180 days they will automatically bypass the seven-day restriction.
Coding & Lookback
Provider Actions & Requirements
Prior Authorization required to exceed 7-day limit
When a patient is not otherwise exempt, any initial short-acting opioid prescription that exceeds a seven (7) day supply requires submission of a Prior Authorization to SFHP to obtain an exception.
Subsequent prescriptions bypass initial 7-day edit
Subsequent opioid prescriptions for the same patient bypass the seven-day initial supply restriction, but remain subject to existing SFHP and legal limits on refills and day supply.
- Standard SFHP and legal limits (for example, the prior 120-tablet limit) continue to apply to refills and day supply.
Prior Authorization documentation requirements
Prior Authorization requests to exceed the seven-day initial supply must include the clinical rationale for exceeding seven days and the expected duration of treatment; for new members on chronic opioids the PA must include the diagnosis and expected duration of therapy.
- Include clinical rationale and expected duration when submitting a PA for >7 days.
- For new SFHP members with historic opioid use, include the diagnosis and expected duration of therapy in the PA.
Trigger: no paid opioid claim in prior 180 days
If the member has no paid opioid claim in the prior 180 days, an initial short-acting opioid prescription greater than seven (7) days will trigger the edit and require a Prior Authorization (including clinical rationale and expected duration) to obtain an exception.
- A prescription is considered initial when there are no paid opioid claims in the last 180 days.
- Prescribers must submit a PA when writing >7 days for an initial prescription to bypass the restriction.
Background
The policy’s clinical rationale is to limit the duration of initial short-acting opioid exposure for acute pain in order to reduce the risk of dependence and transition to long-term opioid use. By restricting first-time short-acting opioid prescriptions to a shorter supply, the policy aligns with public-health efforts to curb opioid-related harms while preserving exemptions (for example, active cancer treatment) where longer initial therapy may be clinically justified.
Definitions
Initial Therapy Criteria
Initial therapy limits
Initial short-acting opioid prescription rules
Policy effective date: May 2018.
Continuation / Subsequent Therapy
Subsequent opioid prescriptions
Subsequent therapy for the same patient
Subsequent prescriptions are not subject to the 7-day initial limit but must comply with other quantity limits and legal requirements.
Quantity Limits
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.